YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

St. John's Heart Institute offers drug-eluting stents

Posted online

St. John's heart patients now have an opportunity to receive one of the most highly anticipated medical products for treating clogged coronary arteries, according to a May 13 news release.

The drug-eluting Stent received approval by the Food and Drug Administration in late April amid media hype for its demonstrated positive clinical results in eliminating tissue re-growth inside the artery. Re-growth can lead to re-blockage (restenosis) and potential repeat procedures.

Cardiologists implanted the first Stent at St. John's April 24 at St. John's Regional Health Center's state-of-the-art cardiac catheterization lab in Springfield.

"We equate this day to the day we first began angioplasty procedures," said Ron Smalling, MD, just before starting the hospital's first drug-eluting Stent procedure on patient Harold Blakemore. "It has the potential of sparing tens of thousands of patients the need for repeat angioplasties or bypass surgery."

The new Stent elutes the drug Sirolimus that has a unique mechanism of action that selectively halts smooth muscle cell proliferation, which is the primary cause of scar tissue that can lead to reblocked arterial vessels.

The drug also reduces inflammatory cell activity in the vessel wall, minimizing the potential for side effects that could delay vessel healing.

Cardiologists warn, however, that the drug-eluting Stents aren't indicated for all cases. They are not recommended for vessels that have experienced restenosis, for instance. Smalling urges patients to discuss treatments with their physicians to get an understanding of the Stent.

Each year, more than 1 million patients in the United States are treated with balloon angioplasty, and 80 percent of them receive conventional coronary Stents.

According to Lisa Hutchison, RN, director of St. John's cardiac catheterization lab, 2,000 Stent procedures are performed each year. About 50 percent of those are re-treated in the same vessel within the first year, when the treatment fails to keep the artery open.

Comments

No comments on this story |
Please log in to add your comment
Editors' Pick
Fall 2026 Architects & Engineers Project Report

This installment of Springfield Business Journal’s Architects & Engineers Project Report showcases 26 endeavors by area design and engineering professionals.

Most Read
Update cookies preferences